Clay Smith, MD
Clinical Professor, Medicine-Hematology

Medical School:
  • MD, University of Texas Southwestern Medical Center at Dallas Southwestern Medical School (1984)
Undergraduate School:
  • BA, Rice University (TX) (1979)
  • Parkland Memorial Hospital, Dallas, Texas (1985)
  • New York Presbyterian Hospital (Cornell Campus) Program, Internal Medicine (1987)
  • Memorial Sloan-Kettering Cancer Center Program, Hematology and Oncology (1992)
Languages: English
Department: Medicine-Hematology

Professional Titles

  • Director, Blood Disorders and Cell Therapies Center

Research Interests

My research is focused on precision medicine for hematologic malignancies


  • Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 Feb 1;27(3):819-830. PubMed PMID: 33109736
  • Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, Pollyea DA. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020 Jul 14;4(13):3102-3108. PubMed PMID: 32634235
  • Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 May 26;4(10):2227-2235. PubMed PMID: 32442301
  • Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 Apr;10(4):536-551. PubMed PMID: 31974170
  • Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax? ?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30;:1-9. [Epub ahead of print] PubMed PMID: 33375853
  • Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018 Nov 12;34(5):724-740.e4. PubMed PMID: 30423294
  • Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR. Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415]. Biol Blood Marrow Transplant. 2017 Mar;23(3):534. PubMed PMID: 27789277
  • Kariminia A, Ivison S, Ng B, Rozmus J, Sung S, Varshney A, Aljurf M, Lachance S, Walker I, Toze C, Lipton J, Lee SJ, Szer J, Doocey R, Lewis I, Smith C, Chaudhri N, Levings MK, Broady R, Devins G, Szwajcer D, Foley R, Mostafavi S, Pavletic S, Wall DA, Couban S, Panzarella T, Schultz KR. CD56(bright) natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 2017 Nov;102(11):1936-1946. PubMed PMID: 28935847
  • Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant. 2016 Dec;51(12):1588-1593. PubMed PMID: 27400068
  • Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14;291(42):21984-22000. PubMed PMID: 27573247
  • Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015;815:349-59. PubMed PMID: 25427917
  • Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. PubMed PMID: 26553768
  • Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
  • Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci. 2014 Mar;1310:58-68. PubMed PMID: 24641679
  • Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL. Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. PubMed PMID: 24061865
View All (15 Total) View Less

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court
3rd floor, Anschutz Cancer Pavilion
Aurora, CO 80045

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

  • Internal Medicine, Board Certification (1989)
  • Hematology, Board Certification (1994, 2016)
Conditions & Treatments
  • Cancers - Leukemia (Adult Acute)
  • Cancers - Blood and Marrow Transplant
  • Cancers
Clinical Interests
Personalized medicine

Care Philosophy
I'm keen to see persons with blood cancers get the latest in treatment advances as well as the most compassionate and supportive care.

Personal Interests
Dr. Smith received his bachelor’s degree from Rice University and his MD from University of Texas, Southwestern Medical School where he also completed his internship. The majority of his post-graduate training was completed in New York City, with residency at NY Hospital/Cornell Medical Center and a fellowship in Hematology and Oncology at Memorial Sloan Kettering Cancer Center. He performed advanced fellowship training in bone marrow transplantation (BMT) at Stanford University. Dr. Smith’s first faculty appointment was as an Assistant Professor at Duke University where he established a highly successful research program specifically focused on gene transfer strategies for therapeutic modification of hematopoietic cells (HSCs) and novel methods of high throughput flow cytometric analysis. Dr. Smith has also served in appointments with the Moffitt Cancer Center, the University of British Columbia, Vancouver, and University of Pittsburgh. Throughout the course of his career, Dr. Smith has published over 150 scientific articles. He was recruited to serve as the program director of the Blood Cancer & BMT Program at the University of Colorado in 2012, and currently is the Associate Chief of the Division of Hematology and the Medical Director of the Innovation Centers at CU and UCHealth.

General Information

Medical Schools:
  • MD, University of Texas Southwestern Medical Center at Dallas Southwestern Medical School (1984)
Undergraduate Schools:
  • BA, Rice University (TX) (1979)
  • Parkland Memorial Hospital, Dallas, Texas (1985)
Residency Programs:
  • New York Presbyterian Hospital (Cornell Campus) Program, Internal Medicine (1987)
  • Memorial Sloan-Kettering Cancer Center Program, Hematology and Oncology (1992)
Languages: English
Department: Medicine-Hematology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile